The US company, "Pfizer", announced, that it will allow low- and middle-income countries across the world to manufacture and distribute its new anti-Covid 19 drugs at low cost.
The move comes as an attempt to increase global supply in 95 poor countries, while this move helps treat patients with the Coronavirus.
But the company has not taken a similar decision regarding its anti-virus vaccine, according to the American “Axios” website.
Yesterday, the company asked the US Food and Drug Administration (FDA) to issue an emergency use license for the new drug developed by "PAXLOVID" and anti-COVID -19.
Pfizer said in a statement that it is seeking an emergency use authorization for the oral antiviral developed by "PAXLOVID" as a case treatment for patients at increased risk of hospitalization or death.
The company said in a statement: “The data showed an 89% reduction in the risk of hospitalization or deaths related to COVID-19, among patients treated with the drug.”
It is worth noting that the company faces sharp criticism, for resisting multiple calls to make the composition of its vaccine against the Coronavirus disease available, in order to manufacture and distribute it in countries with the aim of ending the epidemic, especially in poor countries.
On the other hand, Trevor Bedford, an American epidemiologist. said that "the Coronavirus will likely continue to mutate but at a slower rate than in the past."
Trevor Bedford, an assistant professor of bioinformatics in the Department of Vaccines and Infectious Diseases at the Fred Hutchinson Cancer Research Center, wrote on his Twitter account on Monday that he expects new mutations to occur to help the virus escape the body's immune response, but these mutations will occur at a slower rate than the last year.
He went on to say that he thinks the world is already seeing a slowdown between 2020 and this year."
Follow the latest news on Google News
